Skip to main content
Back
Watch Compare

Cellectar Biosciences, Inc.

Data quality: 83%
CLRB
NASDAQ Manufacturing Chemicals
$2.76
▼ $0.07 (-2.47%)
Mkt Cap: 12.00 M
Price
$2.83
Mkt Cap
12.00 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -23.12 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-309.48%
Below sector avg (-54.47%)
ROIC-206.96%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio2.77
Interest CoverageN/A

Valuation

PE (TTM|NTM)
-0.55 | -0.89
Above sector avg (-1.49)
P/B Ratio1.50
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1385 peers)
Metric Stock Sector Median
P/E -0.6 -1.5
P/B 1.5 1.6
ROE % -309.5 -54.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

3 analysts
Buy
Current
$2.76
+1107.7%
Target
$33.33
$10.00
$14.00
$76.00
Forecast
Forward P/E -0.89
Forward EPS -$3.10
Est. Revenue 11.48 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$3.10
-$5.37 – -$1.51
 11.48 M 3
FY2026 -$4.20
-$5.54 – -$2.85
 0.0 2

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$1.23 -$0.53 +56.7%
Q32025 -$2.53 -$1.41 +44.2%
Q22025 -$3.70 -$3.39 +8.4%
Q12025 -$4.90 -$4.20 +14.3%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -21.79 M
ROE -309.48% ROA -153.88%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -23.12 M
ROIC -206.96% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.77
Interest Coverage N/A Asset Turnover N/A
Working Capital 8.71 M Tangible Book Value 8.00 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.55 Forward P/E -0.89
P/B Ratio 1.50 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 1.05 Fwd Earnings Yield N/A
FCF Yield -192.71%
Market Cap 12.00 M Enterprise Value -554,710.0
Per Share
EPS (Diluted TTM) -8.35 Revenue / Share N/A
FCF / Share -5.45 OCF / Share -5.45
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 106.12%
SBC-Adj. FCF -26.35 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -21.79 M -44.58 M -37.98 M -28.60 M -24.12 M
EPS (Diluted) -8.35 -1.40 -3.11 -4.05 -0.76
Gross Profit — — — — —
Operating Income -22.98 M -51.78 M -38.96 M -28.81 M -24.13 M
EBITDA — — — — —
R&D Expenses 11.50 M 26.14 M 28.21 M 19.22 M 17.59 M
SG&A Expenses — — — — —
D&A 213,597.0 291,653.0 192,375.0 148,435.0 —
Interest Expense — — — — —
Income Tax 66,000.0 66,000.0 -60,000.0 -60,000.0 —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 14.98 M 25.47 M 12.08 M 21.59 M 37.20 M
Total Liabilities 5.06 M 9.80 M 13.43 M 6.08 M 4.16 M
Shareholders' Equity 8.54 M 14.29 M -1.36 M 15.51 M 33.05 M
Total Debt — — — — —
Cash & Equivalents 13.20 M 23.29 M 9.56 M 19.87 M 35.70 M
Current Assets 14.04 M 24.25 M 10.45 M 20.53 M 36.57 M
Current Liabilities 4.75 M 9.39 M 12.94 M 5.53 M 3.99 M